Drug Delivery and Molecular Sensing Research Program (Project-004)

药物输送和分子传感研究计划： 项目摘要 药物传递和分子传感(DDMS)计划是PCCR的技术分支， 使成像、分离、生物传感和定向递送方面取得进展，可应用于基本 癌症研究中的发现和翻译工作。DDMS由来自11个国家的19名教职员工组成 普渡大学的学术部门。DDMS提供细胞和组织成像的集体专业知识，设计 用于药物测试的药物输送载体和仿生平台，以及将 与其他PCCR研究计划协同推进我们对癌症驱动的理解 在分子水平上的过程。在上一次CCSG资助期间，从以下人员中招募了五名新成员 应用科学和工程部门，进一步增强了DDMS在生物医学领域的多种优势 成像、生物分析分离和体外测试。DDMS成员共享 癌症检测和增强癌症效果的新技术的发明和应用 治疗。DDMS在这方面卓有成效，在2010至2010年间共撰写了519篇论文 2014年5月，20%代表与PCCR成员和其他NCI指定的癌症患者的协作互动 中锋。发展和社会事务部的努力由410万美元的直接费用、同行审查的外部支助维持。 DDMS围绕三个研究主题构建：(1)癌症生物学和临床的成像工具 癌症分析，在晚期脑癌的成像和新的发现方面取得突破 与癌症进展相关的代谢物标记物；(2)生物分子研究技术 过程和生物标记物检测，产生了解码表观遗传途径的新方法 检测活细胞中的RNA转录本，以及从临床血液中检测罕见癌细胞的新平台 用于评估癌症治疗对切除组织样本的影响的样本；以及(3)分子 发现和验证分子给药系统的药物给药结合物和材料 在癌症和免疫学的界面上寻找新的靶点，并针对不同的癌症类型靶向配体。全 在这些研究工作中，与PCCR的其他研究计划(例如， MC和CSB)，并得到了PCCR共享资源的关键支持；此外，几项研究 进步导致了新的创业公司的创建和知识产权的产生。 DDMS计划负责人一直在积极更新方向，组织专题研讨会，招募 与癌症研究中心合作，为癌症研究项目的新成员提供指导 比索发现集团，并围绕癌症相关主题组建团队，目标是提交 多名研究人员的研究资助。例如，体外测试平台可以解决未满足的需求 基于多模式的药物递送研究、基于代谢物的癌症标志物时空分析 用于研究微环境对血管生成的影响的成像和三维组织培养模型。

Drug Delivery and Molecular Sensing Research Program: Project Summary The Drug Delivery and Molecular Sensing (DDMS) Program serves as the technology arm of the PCCR, enabling advances in imaging, separations, biosensing and targeted delivery, that can be applied toward basic discoveries and translational efforts in cancer research. DDMS is comprised of 19 faculty members from 11 Purdue academic departments. DDMS provides collective expertise in cellular and tissue imaging, design of drug delivery vehicles and biomimetic platforms for drug testing, and novel bioanalytical methods that couple synergetically with other PCCR Research Programs and that advance our understanding of cancer-driven processes at the molecular level. During this last CCSG funding period, five new members were recruited from the applied sciences and engineering departments, further increasing DDMS's diverse strengths in biomedical imaging, bioanalytical separations, and in vitro testing. DDMS members share a common thread in the invention and application of new technologies for cancer detection, and for enhancing the effects of cancer treatment. DDMS has been highly productive in this regard, having producing 519 papers between 2010 and May 2014, 20% representing collaborative interactions with PCCR members and other NCI-designated cancer centers. DDMS efforts are sustained by $4.1 million of direct cost, peer-reviewed extramural support. DDMS is structured around three Research Themes: (1) Imaging Tools for Cancer Biology and Clinical Cancer Analysis, with breakthroughs in the imaging of advanced brain cancers and in the discovery of new metabolite-based markers associated with cancer progression; (2) Technologies for Investigating Biomolecular Processes and Biomarker Detection, which has produced novel methods for decoding epigenetic pathways and detecting RNA transcripts in live cells, and new platforms for detecting rare cancer cells from clinical blood samples or for evaluating the impact of cancer therapy on resected tissue samples; and (3) Molecular Conjugates and Materials for Drug Delivery, which has discovered and validated molecular delivery systems for new targets at the interface of cancer and immunology, and targeting ligands for different cancer types. All of these research efforts have resulted in new collaborations with PCCR's other Research Programs (e.g. CIS, MC, and CSB) and have been critically supported by PCCR Shared Resources; moreover, several research advances have resulted in the creation of new startup companies and the generation of intellectual property. DDMS Program Leaders have been active in renewing directions by organizing topical workshops, recruiting and providing mentorship to new members with cancer-focused research projects, in cooperation with the PESO Discovery Group, and assembling teams around cancer-related themes that target the submission of multi-investigator research grants. Examples include in vitro testing platforms that can address unmet needs in drug delivery research, spatiotemporal analysis of metabolite-based cancer markers based on multimodal imaging, and 3-D tissue culture models for investigating microenvironmental effects on vasculogenesis.